Readoutin 14d
Dr. Falk Pharma GmbH — Budesonide
Phase 3 primary completion: Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE.
- Date
- Dec 2026
- Type
- Readout
- Indication
- Eosinophilic Esophagitis
Readoutin 14d
Phase 3 primary completion: Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE.
The weekly brief is free. Pro adds reminders 7 days and 1 day before.